Most Recent Tools for Practice
Tools for Practice #299 – Cardiovascular prevention trials: Now calling colchicine to the stand
Is colchicine effective for secondary cardiovascular prevention?
BOTTOM LINE: Daily low-dose colchicine in people with coronary artery disease (CAD) lowers the risk of cardiovascular events by ~1%/year (relative risk reduction 25-30%), but increases the risk of gastrointestinal events (mostly diarrhea) by ~2% and has no effect on mortality. Read More
Tools for Practice #298 – Long COVID: A (somewhat) short summary of risks, symptoms, and natural course
How common is Long COVID, what are the symptoms and how long does it last?
BOTTOM LINE: The presence of Long Covid (persistence of ≥1 symptom after acute infection) is found in 20-80% at 60 days post-infection, varying widely based on study design and population. Risk factors include increased age, increased severity of initial infection and female sex. Fatigue, dyspnea, and cognitive effects are the most common symptoms, but the list is long. Symptoms decline over time, but some patients will have persistent symptoms at and possibly beyond 8 months. Read More
Tools for Practice #297 – Opening a can of helminths: Ivermectin for COVID-19
Does ivermectin improve clinical outcomes in COVID-19?
BOTTOM LINE: The best available evidence does not show that ivermectin improves clinically important outcomes in COVID-19. Use in COVID-19 is discouraged. Read More
Tools for Practice #296 – Frequent migraines are a headache: Can biologics help?
What is the efficacy of Calcitonin Gene Related Peptide (CGRP) inhibitors in migraine prophylaxis?
BOTTOM LINE: For patients with episodic and chronic migraines, treating 5-8 patients with a CGRP-inhibitor will lead to one patient experiencing at least a 50% reduction in monthly migraine days compared to placebo. From baseline, a decrease of 1-2 monthly migraine days may be seen. Cost may limit use. Read More
Tools for Practice #295 – Mission Slimpossible: Semaglutide for weight loss
Is semaglutide effective for weight loss?
BOTTOM LINE: Used with lifestyle changes, 2.4mg weekly subcutaneous semaglutide resulted in an average 10-15% loss in weight (10- 15kg) over 68 weeks versus 2-3% (3-4kg) with placebo. Most (70- 80%) semaglutide participants lost 5% or more of their body weight. About ¾ of patients experienced gastrointestinal side effects, but few stop. Weight regain occurs once the medication is stopped. Read More
When creating primary care education and programs, the PEER team focuses on minimizing bias, patient orientated outcomes, shared decision making, collaboration and most importantly simplicity.
Who is PEER?
Patients, Experience, Evidence and Research (PEER) was formed between a group of primary care providers who shared a common belief that evidence should be made accessible to all primary care providers.